SYNGENE

Syngene International Limited

Contract research, development and manufacturing organisation for pharma and biotech clients

Healthcare›Healthcare›Healthcare Services›Healthcare Research, Analytics & Technology

syngeneintl.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹386.10
Market cap
15,587 Cr
Stock P/E
70.5
P/B
3.21
Dividend yield
0.3%
ROE (FY26)
6.5%
ROCE (FY26)
9.5%
Operating margin (FY26)
12.5%
Debt / equity (FY26)
0.0019
OCF / EBITDA (FY26)
99.6%
OCF / EBITDA (3Y)
105.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Syngene International provides contract research, development and manufacturing services to global biotech and pharmaceutical companies, working with around 400 global customers that include BMS, GSK, Zoetis and Merck KGaA (April 2026 press release).

Company snapshot

1stBy market cap

Ranked among 5 companies in Healthcare Research, Analytics & Technology.

What we see

Positives
  • ✓105% of operating profit came in as cash over the last three years — profits are backed by real cash.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales910 Cr854 Cr917 Cr790 Cr891 Cr944 Cr1,018 Cr875 Cr911 Cr917 Cr1,037 Cr736 Cr
Operating expenses (approx.)656 Cr622 Cr600 Cr620 Cr646 Cr660 Cr674 Cr668 Cr711 Cr708 Cr733 Cr645 Cr
EBITDA254 Cr232 Cr317 Cr170 Cr245 Cr284 Cr344 Cr206 Cr200 Cr209 Cr303 Cr91 Cr
OPM %27.9%27.1%34.6%21.5%27.5%30.1%33.8%23.6%21.9%22.8%29.3%12.3%
Other income22 Cr29 Cr16 Cr18 Cr17 Cr18 Cr19 Cr18 Cr15 Cr15 Cr22 Cr25 Cr
Interest13 Cr11 Cr13 Cr12 Cr13 Cr12 Cr16 Cr12 Cr13 Cr12 Cr12 Cr10 Cr
Depreciation105 Cr108 Cr111 Cr107 Cr111 Cr109 Cr106 Cr111 Cr117 Cr114 Cr112 Cr112 Cr
Profit before tax151 Cr138 Cr209 Cr101 Cr137 Cr181 Cr241 Cr101 Cr85 Cr28 Cr196 Cr-19 Cr
Tax %22.7%19.3%9.8%25.3%22.7%27.5%23.8%14.4%21.2%47.2%24.5%53.1%
Net profit117 Cr112 Cr189 Cr76 Cr106 Cr131 Cr183 Cr87 Cr67 Cr15 Cr148 Cr-9 Cr
EPS (₹)₹2.90₹2.78₹4.70₹1.89₹2.64₹3.27₹4.56₹2.16₹1.67₹0.37₹3.68₹-0.22

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,423 Cr1,826 Cr2,012 Cr2,184 Cr2,604 Cr3,193 Cr3,489 Cr3,642 Cr3,739 CrSign in free for the trailing twelve months
Operating expenses (approx.)958 Cr1,289 Cr1,394 Cr1,513 Cr1,808 Cr2,259 Cr2,474 Cr2,601 Cr2,820 CrSign in free for the trailing twelve months
EBITDA465 Cr537 Cr618 Cr672 Cr796 Cr934 Cr1,014 Cr1,042 Cr919 CrSign in free for the trailing twelve months
OPM %32.7%29.4%30.7%30.8%30.6%29.3%29.1%28.6%24.6%Sign in free for the trailing twelve months
Other income62 Cr75 Cr82 Cr65 Cr53 Cr71 Cr91 Cr72 Cr71 CrSign in free for the trailing twelve months
Interest23 Cr32 Cr35 Cr28 Cr24 Cr45 Cr47 Cr53 Cr49 CrSign in free for the trailing twelve months
Depreciation131 Cr164 Cr219 Cr275 Cr310 Cr367 Cr426 Cr433 Cr453 CrSign in free for the trailing twelve months
Profit before tax373 Cr415 Cr517 Cr469 Cr484 Cr594 Cr621 Cr660 Cr411 CrSign in free for the trailing twelve months
Tax %18.0%20.2%20.3%13.7%18.3%21.8%17.8%24.8%22.9%Sign in free for the trailing twelve months
Net profit305 Cr332 Cr412 Cr405 Cr396 Cr464 Cr510 Cr496 Cr317 CrSign in free for the trailing twelve months
EPS (₹)₹15.47₹16.77₹10.38₹10.18₹9.94₹11.59₹12.71₹12.35₹7.87Sign in free for the trailing twelve months
Dividend payout %———0.0%0.0%8.6%9.9%10.1%15.9%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital200 Cr200 Cr400 Cr400 Cr401 Cr401 Cr402 Cr403 Cr403 Cr
Reserves1,520 Cr1,768 Cr1,776 Cr2,421 Cr2,897 Cr3,217 Cr3,856 Cr4,324 Cr4,436 Cr
Borrowings664 Cr552 Cr309 Cr772 Cr790 Cr575 Cr142 Cr120 Cr9 Cr
Other liabilities805 Cr1,183 Cr1,678 Cr1,290 Cr1,477 Cr1,638 Cr1,752 Cr1,950 Cr2,206 Cr
Total liabilities3,189 Cr3,704 Cr4,163 Cr4,883 Cr5,564 Cr5,831 Cr6,152 Cr6,796 Cr7,055 Cr
Fixed assets (net)1,012 Cr1,323 Cr1,877 Cr2,032 Cr2,123 Cr2,383 Cr2,378 Cr2,323 Cr2,545 Cr
CWIP155 Cr274 Cr234 Cr237 Cr346 Cr177 Cr837 Cr1,261 Cr1,040 Cr
Investments158 Cr756 Cr812 Cr740 Cr1,073 Cr967 Cr589 Cr681 Cr773 Cr
Inventories86 Cr43 Cr25 Cr60 Cr179 Cr333 Cr239 Cr156 Cr141 Cr
Trade receivables267 Cr339 Cr398 Cr339 Cr508 Cr529 Cr442 Cr527 Cr509 Cr
Cash & bank253 Cr165 Cr193 Cr323 Cr262 Cr90 Cr86 Cr367 Cr229 Cr
Other assets1,258 Cr804 Cr623 Cr1,152 Cr1,073 Cr1,353 Cr1,582 Cr1,482 Cr1,818 Cr
Total assets3,189 Cr3,704 Cr4,163 Cr4,883 Cr5,564 Cr5,831 Cr6,152 Cr6,796 Cr7,055 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity446 Cr630 Cr677 Cr701 Cr581 Cr824 Cr1,042 Cr1,168 Cr915 Cr
Cash from investing-349 Cr-646 Cr-428 Cr-628 Cr-611 Cr-656 Cr-496 Cr-745 Cr-860 Cr
Cash from financing-79 Cr-72 Cr-225 Cr58 Cr-31 Cr-342 Cr-551 Cr-142 Cr-215 Cr
Net cash flow18 Cr-88 Cr23 Cr130 Cr-61 Cr-172 Cr-4 Cr281 Cr-138 Cr
Free cash flow (OCF − Capex)83 Cr47 Cr34 Cr255 Cr105 Cr305 Cr531 Cr398 Cr547 Cr

Ratios

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %16.6%17.8%22.2%13.8%12.4%15.2%15.2%14.7%9.5%
ROE %17.8%16.8%18.9%14.4%12.0%12.8%12.0%10.5%6.5%
Debtor days686872577160465350
Inventory days79311839851341006156
Days payable187161156159110104107138139
Cash conversion cycle-40-62-66-64469139-25-33
OCF / EBITDA %96.0%117.4%109.6%104.4%72.9%88.1%102.7%112.1%99.6%
OCF / EBITDA % (3 years)——108.3%110.0%93.9%87.6%89.1%101.4%105.0%
Debt / equity0.390.280.140.270.240.160.030.030.0019
Current ratio2.201.561.051.591.802.041.711.641.38
Net debt / EBITDA0.880.720.190.670.660.520.06-0.24-0.24